Adenosine as an Adjunct Therapy in ST Elevation Myocardial Infarction Patients: Myth or Truth?

Cardiovascular Drugs and Therapy

Volumn 29, Issue 5, 2015, Pages 481-493

  Kassimis, George ^a   Davlouros, Periklis ^b   Patel, Niket ^c   De Maria, Gianluigi ^c   Kallistratos, Manolis S ^a   Kharbanda, Rajesh K ^c   Manolis, Athanasios J ^a   Alexopoulos, Dimitrios ^b   Banning, Adrian P ^c  

^a IASO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Adenosine; Microvascular obstruction; No reflow; Reperfusion injury; ST elevation myocardial infarction

Indexed keywords

ADENOSINE; CARDIOTONIC AGENT;

ARTICLE; CARDIAC PATIENT; ELECTROCARDIOGRAPHY; HEART INFARCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; HIGH RISK PATIENT; HUMAN; NO REFLOW PHENOMENON; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PERCUTANEOUS CORONARY INTERVENTION; PROCEDURES;

ADENOSINE; CARDIOTONIC AGENTS; HUMANS; INFUSIONS, INTRA-ARTERIAL; INFUSIONS, INTRAVENOUS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84946497315     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-015-6606-5     Document Type: Article

References (114)

1. Gibson CM, Schoming A. Coronary and myocardial angiography. Angiographic assessment of both epicardial and myocardial perfusion. Circulation. 2004;109:3096–105.
2. De Maria GL, Patel N, Kassimis G, Banning AP. Spontaneous and procedural plaque embolisation in native coronary arteries: pathophysiology, diagnosis, and prevention. Sci(Cairo). 2013;2013:364247.
3. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54:281–92.
4. Galiuto L, Lombardo A, Maseri A, et al. Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation. Heart. 2003;89:731–7.
5. Jaffe R, Charron T, Puley G, et al. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008;117:3152–6.
6. Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;55:2383–9.
7. Rezkalla SH, Kloner RA. Coronary no reflow phenomenon: from the experimental laboratory to the cardiac catherization laboratory. Catheter Cardiovasc Interv. 2008;72:950–7.
8. Klein LW, Kern MJ, Berger P, et al. Society of cardiac angiography and interventions: suggested management of the no-reflow phenomenon in the cardiac catherization laboratory. Catheter Cardiovasc Interv. 2003;60:194–201.
9. Moens AL, Claeys MJ, Timmermans JP, Vrints CJ. Myocardial ischemia/reperfusion injury, a clinical view on a complex pathophysiological process. Int J Cardiol. 2005;100:179–90.
10. Van’t Hof AW, Liem A, de Boer MJ, Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group. Lancet. 1997;350:615–9.
11. Brodie BR, Stuckey TD, Hansen C, et al. Relation between electrocardiographic ST-segment resolution and early and late outcomes after primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2005;95:343–8.
12. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125–30.
13. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI study group. N Engl J Med. 1985;312:932–6.
14. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93:879–88.
15. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002;105:1909–13.
16. Van’t Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial infarction Study Group. Circulation. 1998;97:2302–6.
17. Hozumi T, Kanzaki Y, Ueda Y, et al. Coronary flow velocity analysis during short term follow up after coronary reperfusion: use of transthoracic Doppler echocardiography to predict regional wall motion recovery in patients with acute myocardial infarction. Heart. 2003;89:1163–8.
18. Kamp O, Lepper W, Vanoverschelde JL, et al. Serial evaluation of perfusion defects in patients with a first acute myocardial infarction referred for primary PTCA using intravenous myocardial contrast echocardiography. Eur Heart J. 2001;22:1485–95.
19. Uren NG, Crake T, Lefroy DC, de Silva R, Davies GJ, Maseri A. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med. 1994;331:222–7.
20. Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765–72.
21. Lepper W, Hoffmann R, Kamp O, et al. Assessment of myocardial reperfusionby intravenous myocardial contrast echocardiography and coronary flow reserve after primary percutaneous transluminal coronary angioplasty [correction of angiography] in patients with acute myocardial infarction. Circulation. 2000;101:2368–74.
22. Cuculi F, Dall’Armellina E, Manlhiot C, et al. Early change in invasive measures of microvascular function can predict myocardial recovery following PCI for ST-elevation myocardial infarction. Eur Heart J. 2014;35:1971–80.
23. Feldman LJ, Himbert D, Juliard JM, et al. Reperfusion syndrome: relationship of coronary blood flow reserve to left ventricular function and infarct size. J Am Coll Cardiol. 2000;35:1162–9.
24. Feldman LJ, Coste P, Furber A, et al. Incomplete resolution of ST-segment elevation is a marker of transient microcirculatory dysfunction after stenting for acute myocardial infarction. Circulation. 2003;107:2684–9.
25. Fearon WF, Shah M, Ng M, et al. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008;51:560–5.
26. Payne AR, Berry C, Doolin O, et al. Microvascular resistance predicts myocardial salvage and infarct characteristics in ST-elevation myocardial infarction. J Am Heart Assoc. 2012;1:e002246.
27. Araszkiewicz A, Grajek S, Lesiak M, et al. Effect of impaired myocardial reperfusion on left ventricular remodelling in patients with anterior wall myocardial infarction treated with primary coronary intervention. Am J Cardiol. 2006;98:725–8.
28. Brosh D, Asali AR, Mayer A, et al. Effect of no-reflow during primary percutaneous intervention for acute myocardial infarction on six-month mortality. Am J Cardiol. 2007;99:442–5.
29. Kloner RA. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther. 2011;16:244–50.
30. Durante A, Camici PG. Novel insights into an “old” phenomenon: the no reflow. Int J Cardiol. 2015;187:273–80.
31. Barrabes JA, Garcia-Dorado D, Mirabet M, et al. Antagonism of selectin function attenuates microvascular platelet deposition and platelet-mediated myocardial injury after transient ischemia. J Am Coll Cardiol. 2005;45:293–9.
32. Barrabes JA, Inserte J, Mirabet M, et al. Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts. Thromb Haemost. 2010;104:128–35.
33. Mirabet M, Garcia-Dorado D, Inserte J, et al. Platelets activated by transient coronary occlusion exacerbate ischemia reperfusion injury in rat hearts. Am J Physiol Heart Circ Physiol. 2002;283:H1134–41.
34. Mirabet M, Garcia-Dorado D, Ruiz-Meana M, Barrabes JA, Soler-Soler J. Thrombin increases cardiomyocyte acute cell death after ischemia and reperfusion. J Mol Cell Cardiol. 2005;39:277–83.
35. Garcia-Dorado D, Agulló L, Sartorio CL, Ruiz-Meana M. Myocardial protection against reperfusion injury: the cGMP pathway. Thromb Haemost. 2009;101:635–42.
36. Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS): a 1-year follow-up study. Lancet. 2008;371:1915–20.
37. Sardella G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXPIRA (thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention) prospective, randomized trial. J Am Coll Cardiol. 2009;53:309–15.
38. Liistro F, Grotti S, Angioli P, et al. Impact of thrombus aspiration on myocardial tissue reperfusion and left ventricular functional recovery and remodeling after primary angioplasty. Circ Cardiovasc Interv. 2009;2:376–83.
39. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012;307:1817–26.
40. Dudek D, Mielecki W, Burzotta F, et al. Thrombus aspiration followed by direct stenting: a novel strategy of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. Results of the Polish-Italian-Hungarian Randomized ThrombEctomy Trial (PIHRATE Trial). Am Heart J. 2010;160:966–72.
41. Frobert O, Lagerqvist B, Olivecrona GK, et al. TASTE trial: thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013;369:1587–97.
42. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med. 2008;358:557–67.
43. Tomassini F, Gagnor A, Montali N, et al. Impact of thrombus aspiration during primary percutaneous coronary intervention in cardiogenic shock complicating ST-segment elevation myocardial infarction. Cardiovasc Revasc Med. 2013;14:307–10.
44. Kumbhani DJ, Bavry AA, Desai MY, Bangalore S, Bhatt DL. Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J Am Coll Cardiol. 2013;62:1409–18.
45. De Luca G, Navarese EP, Suryapranata H. A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol. 2013;166:606–12.
46. Jolly SS, Cairns JA, Yusuf S, et al. TOTAL investigators. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. 2015;372:1389–98.
47. Thiele H, Schindler K, Friedenberger J, et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation. 2008;118:49–57.
48. Bartorelli AL, Trabattoni D, Galli S, Grancini L, Cozzi S, Ravagnani P. Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA. Catheter Cardiovasc Interv. 1999;48:211–3.
49. Kakkar AK, Moustapha A, Hanley HG, et al. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv. 2004;61:31–4.
50. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895–903.
51. Stone GW, McLaurin BT, Cox DA, et al. ACUITY Investigators. Bivalirudin for patients withacute coronary syndromes. N Engl J Med. 2006;355:2203–16.
52. Stone GW, Witzenbichler B, Guagliumi G, et al. HORIZONS-AMI trial investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218–30.
53. Ishihara M, Sato H, Tateishi H, et al. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J. 1996;132:959–63.
54. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft interventions: comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn. 1996;39:113–8.
55. Werner GS, Lang K, Kuehnert H, Figulla HR. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv. 2002;57:444–51.
56. Weyrens FJ, Mooney J, Lesser J, Mooney MR. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol. 1995;75:849–50.
57. Su Q, Li L, Liu Y. Short-term effect of verapamil on coronary no-reflow associated with percutaneous coronary intervention in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Cardiol. 2013;36:E11–6.
58. Skelding KA, Goldstein JA, Mehta L, Pica MC, O’Neill WW. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv. 2002;57:305–9.
59. Ota S, Nishikawa H, Takeuchi M, et al. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J. 2006;70:1099–104.
60. Kunadian V, Zorkun C, Williams SP, et al. Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction. J Thromb Thrombolysis. 2008;26:234–42.
61. Amit G, Cafri C, Yaroslavtsev S, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial. Am Heart J. 2006;152:887.e9–14.
62. Kobatake R, Sato T, Fujiwara Y, et al. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessels. 2011;26:379–84.
63. Niccoli G, Rigattieri S, De Vita MR, et al. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroprusside after thrombus aspiration during primary percutaneous coronary intervention for the prevention of microvascular obstruction in acute myocardial infarction: the REOPEN-AMI study (Intracoronary Nitroprusside Versus Adenosine inAcute Myocardial Infarction). JACC Cardiovasc Interv. 2013;6:580–9.
64. Parikh KH, Chag MC, Shah KJ, et al. Intracoronary boluses of adenosine and sodium nitroprusside in combination reverses slow/no-reflow during angioplasty: a clinical scenario of ischemic preconditioning. Can J Physiol Pharmacol. 2007;85:476–82.
65. Pasceri V, Pristipino C, Pelliccia F, et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol. 2005;95:1358–61.
66. Shinozaki N, Ichinose H, Yahikozawa K, Shimada H, Hoshino K. Selective intracoronary administration of nitroprusside before balloon dilatation prevents slow reflow during percutaneous coronary intervention in patients with acute myocardial infarction. Int Heart J. 2007;48:423–33.
67. Wang HJ, Lo PH, Lin JJ, Lee H, Hung JS. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv. 2004;63:171–6.
68. Youssef AA, Wu CJ, Hang CL, et al. Impact of Percu surge device conjugative with intracoronary administration of nitroprusside on no-reflow phenomenon following primary percutaneous coronary intervention. Circ J. 2006;70:1538–42.
69. Claeys MJ, Bosmans J, De Ceuninck M, et al. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfusion injury in patients with acute myocardial infarction. Am J Cardiol. 2004;94:9–13.
70. Desmet W, Bogaert J, Dubois C, et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction. Eur Heart J. 2011;32:867–77.
71. Fokkema ML, Vlaar PJ, Vogelzang M, et al. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial. Circ Cardiovasc Interv. 2009;2:323–9.
72. Grygier M, Araszkiewicz A, Lesiak M, et al. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol. 2011;107:1131–5.
73. Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapyfor acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol. 1999;34:1711–20.
74. Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000;101:2154–9.
75. Micari A, Belcik TA, Balcells EA, et al. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am J Cardiol. 2005;96:1410–5.
76. Petronio AS, De Carlo M, Ciabatti N, et al. Left ventricular remodeling after primary coronary angioplasty in patients treated with abciximab or intracoronary adenosine. Am Heart J. 2005;150:1015.
77. Quintana M, Hjemdahl P, Sollevi A, et al. Left ventricular function and cardiovascular events following adjuvant therapy with adenosine in acute myocardial infarction treated with thrombolysis, results of the ATTenuation by Adenosine of Cardiac Complications (ATTACC) study. Eur J Clin Pharmacol. 2003;59:1–9.
78. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol. 2005;45:1775–80.
79. Stoel MG, Marques KM, de Cock CC, Bronzwaer JG, von Birgelen C, Zijlstra F. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study. Catheter Cardiovasc Interv. 2008;71:283–9.
80. Zhang H, Tian NL, Hu ZY, et al. Three hours continuous injection of adenosine improved left ventricular function and infarct size in patients with ST-segment elevation myocardial infarction. Chin Med J (Engl). 2012;125:1713–9.
81. Vijayalakshmi K, Whittaker VJ, Kunadian B, et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006;92:1278–84.
82. Wallentin L, Becker RC, Budaj A, Investigators PLATO. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.
83. vanGiezen JJ, Sidaway J, Glaves P, Kirk I, Bjorkman JA. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther. 2012;17:164–72.
84. Alexopoulos D, Xanthopoulou I, Tsigkas G et al. Differential effect of Ticagrelor vs Thienopyridine loading on fractional flow reserve: possible implications for clinical practice. circ.ahajournals.org/content/130/Suppl_2/A20443.abstract.
85. Bonello L, Laine M, Kipson N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63:872–7.
86. Park SD, Baek YS, Woo SI, et al. Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial. Trials. 2014;15:151.
87. Garcia-Dorado D, Rodríguez-Sinovas A, Ruiz-Meana M, Inserte J. Protection against myocardial ischemia-reperfusion injury in clinical practice. Rev Esp Cardiol. 2014;67:394–404.
88. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007;370:1483–93.
89. Selker HP, Beshansky JR, Sheehan PR, et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA. 2012;307:1925–33.
90. Lonborg J, Vejlstrup N, Kelbaek H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491–9.
91. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473–81.
92. Thuny F, Lairez O, Roubille F, et al. Postconditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2012;59:2175–81.
93. Botker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375:727–34.
94. Syeda B, Schukro C, Heinze G, et al. The salvage potential of coronary sinus interventions: meta-analysis and pathophysiologic consequences. J Thorac Cardiovasc Surg. 2004;127:1703–12.
95. Windecker S, Kolh P, Alfonso F, et al. ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.
96. Forman MB, Stone GW, Jackson EK. Role of adenosine as adjunctive therapy in acute myocardial infarction. Cardiovasc Drug Rev. 2006;24:116–47.
97. Layland J, Carrick D, Lee M, Oldroyd K, Berry C. Adenosine: physiology, pharmacology, and clinical applications. JACC Cardiovasc Interv. 2014;7:581–91.
98. Ernens I, Bousquenaud M, Lenoir B, Devaux Y, Wagner DR. Adenosine stimulates angiogenesis by up-regulating production of thrombospondin-1 by macrophages. J Leukoc Biol. 2015;97:9–18.
99. Inserte J, Garcia-Dorado D. The cGMP/PKG pathway as a common mediator of cardioprotection: translatability and mechanism. Br J Pharmacol. 2015;172:1996–2009.
100. Villarreal F, Zimmermann S, Makhsudova L, et al. Modulation of cardiac remodeling by adenosine: in vitro and in vivo effects. Mol Cell Biochem. 2003;251:17–26.
101. Kitakaze M, Hori M. Adenosine therapy: a new approach to chronic heart failure. Expert Opin Investig Drugs. 2000;9:2519–35.
102. Garratt KN, Holmes Jr DR, Molina-Viamonte V, et al. Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am Heart J. 1998;136:196–204.
103. Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006;27:2400–5.
104. Quinta ML, Hjemdahl P, Sollevi A, et al. Possible beneficial effects of adenosine as adjuvant therapy to thrombolytic treatment in patients with an acute myocardial infarction and depressed left ventricular function. J Am Coll Cardiol. 2003;41:347A. abstract.
105. Sakuma T, Motoda C, Tokuyama T, et al. Exogenous adenosine triphosphate disodium administration during primary percutaneous coronary intervention reduces no-reflow and preserves left ventricular function in patients with acute anterior myocardial infarction: a study using myocardial contrast echocardiography. Int J Cardiol. 2010;140:200–9.
106. Wang J, Chen Y, Zhi G, et al. Beneficial effect of adenosine on myocardial perfusion treated with primary percutaneous coronary intervention for acute myocardial infarction. Clin Exp Pharmacol Physiol. 2012;39:247–52.
107. Kassimis G, Patel N, Dawkins S, et al. First-in-man report of twelve-hour continuous intravenous adenosine infusion in STEMI patients undergoing primary PCI: assessment of feasibility and effects on coronary flow reserve. Eurointervention (Euro-PCR 2014, oral abstract, Euro14A-OP145).
108. Niccoli G, Spaziani C, Crea F, Investigators REOPEN-AMI. Left ventricular remodeling and 1-year clinical follow-up of the REOPEN-AMI trial. J Am Coll Cardiol. 2014;63:1454–5.
109. Singh M, Shah T, Khosla K, et al. Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Ther Adv Cardiovasc Dis. 2012;6:101–14.
110. Navarese EP, Buffon A, Andreotti F, et al. Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. Atherosclerosis. 2012;222:1–7.
111. Aung Naing K, Li L, Su Q, Wu T, et al. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Cochrane Database Syst Rev. 2013;6:CD009503.
112. Garcia-Dorado D, García-del-Blanco B, Otaegui I, et al. Intracoronary injection of adenosine before reperfusion in patients with ST-segment elevation myocardial infarction: a randomized controlled clinical trial. Int J Cardiol. 2014;177:935–41.
113. Garcia-Dorado D, Otaegui I, Rodriguez Palomares JF, et al. Primary results of the PROMISE trial: myocardial protection with intracoronary adenosine given before reperfusion in patients with STEMI. Eur Heart J. 2014;34 Suppl 1:669.
114. Nazir SA, Khan JN, Mahmoud IZ, et al. The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial. Trials. 2014;15:371.